NASDAQ:SBFM Sunshine Biopharma Q4 2025 Earnings Report $2.11 0.00 (0.00%) Closing price 07/2/2026 04:00 PM EasternExtended Trading$2.12 +0.01 (+0.47%) As of 07/2/2026 07:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Sunshine Biopharma EPS ResultsActual EPS-$4.60Consensus EPS -$2.70Beat/MissMissed by -$1.90One Year Ago EPSN/ASunshine Biopharma Revenue ResultsActual Revenue$8.58 millionExpected Revenue$10.00 millionBeat/MissMissed by -$1.42 millionYoY Revenue GrowthN/ASunshine Biopharma Announcement DetailsQuarterQ4 2025Date4/3/2026TimeDuring Market HoursConference Call DateN/AConference Call TimeN/AUpcoming EarningsSunshine Biopharma's next earnings date is estimated for Tuesday, August 11, 2026, based on past reporting schedules. Conference Call ResourcesEarnings HistoryCompany Profile Sunshine Biopharma Earnings HeadlinesShort Interest in Sunshine Biopharma, Inc. (NASDAQ:SBFM) Decreases By 87.9%June 26, 2026 | americanbankingnews.comSunshine Biopharma (NASDAQ:SBFM) Trading Down 3.8% - Time to Sell?June 23, 2026 | americanbankingnews.comThe energy story near the Grand CanyonA drilling crew near the Grand Canyon confirmed what the IEA calls one of the largest energy resources ever measured - enough to meet global electricity demand 140 times over. They drilled nearly three miles down in just 16 days, a job the Department of Energy projected would take 64. Google signed a 15-year deal. Bill Gates wrote a $100 million check. On July 4th, Washington hands this resource a regulatory edge no other energy source has.July 4 at 1:00 AM | Behind the Markets (Ad)SBFM Share News TodayMay 15, 2026 | uk.investing.comSunshine Biopharma Delays Annual SEC FilingApril 14, 2026 | theglobeandmail.comSunshine Biopharma’s Nora Pharma receives Health Canada approval for domperidoneOctober 28, 2025 | msn.comSee More Sunshine Biopharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Sunshine Biopharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Sunshine Biopharma and other key companies, straight to your email. Email Address About Sunshine BiopharmaSunshine Biopharma (NASDAQ:SBFM) is a biotechnology company focused on the research, development and commercialization of novel drug candidates primarily for oncology. The company specializes in small-molecule therapeutics designed to overcome multidrug resistance and to target hard-to-treat cancers. Its preclinical pipeline emphasizes compounds that intercalate DNA and inhibit topoisomerase II, with the goal of advancing candidates into clinical trials for various solid tumors. Among its lead programs, Sunshine Biopharma is advancing anthracycline-based compounds, including Bisantrene, which has demonstrated activity against breast and prostate cancer cell lines, and Adva-27a, a novel analog being evaluated for glioblastoma multiforme and other drug-resistant malignancies. These molecules are engineered to enhance tumor selectivity and minimize cardiotoxicity commonly associated with traditional anthracyclines. The company is headquartered in Montreal, Canada, and operates research facilities in North America. Sunshine Biopharma collaborates with academic institutions and contract research organizations to conduct preclinical studies and regulatory activities. Leadership is headed by Dr. Bhupinder Kaur Singh, who serves as President and Chief Executive Officer, guiding corporate strategy, research priorities and investor relations.View Sunshine Biopharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 06/29 - 07/03Meta’s AI Compute Push Could Turn Its Massive CapEx Bill Into a Competitive WeaponGeneral Mills Is a 5-Star Turnaround Play for Buy and Hold InvestorsCopper Stocks Are Getting a Bigger Spotlight as Gold’s Rally CracksNike Q4 Beat Masks Core Weakness as Analysts Cut Price TargetsIs the Memory Rally Still Alive After the Semiconductor Sell-Off?Hershey Stock May Be Near a Sweet Spot as Cocoa Pressure Eases Upcoming Earnings PepsiCo (7/9/2026)Delta Air Lines (7/9/2026)Bank of America (7/14/2026)The Goldman Sachs Group (7/14/2026)JPMorgan Chase & Co. (7/14/2026)Wells Fargo & Company (7/14/2026)Citigroup (7/14/2026)Fastenal (7/14/2026)Cintas (7/15/2026)ASML (7/15/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
